KRAS and colorectal carcinoma: Our results showed that CRC PDXs harboring KRAS mutations expressed remarkably higher levels of high-affinity EGFR ligands than KRAS-wild-type tumors, suggesting that the expression levels of EGFR ligands could be used as biomarkers to predict the therapeutic response to EGFR-targeting strategies.